Monoclonal gammopathy of uncertain significance
MONDO:0004225A condition characterized by the presence of a monoclonal gammopathy (MG) in which the clonal mass has not reached a predefined state in which the condition is considered malignant. Up to 25% of cases of monoclonal gammopathy of undetermined significance (MGUS) progress to a B-cell malignancy or myeloma. MGUS may occur in conjunction with various carcinomas, chronic inflammatory and infectious conditions, and other diseases.
Also known as: MGUS, benign monoclonal gammopathy, monoclonal gammopathy Of undetermined significance (MGUS), monoclonal gammopathy of undetermined significance, monoclonal gammopathy of undetermined significance (MGUS), monoclonal gammopathy of undetermined significance (morphologic abnormality), monoclonal gammopathy of unknown significance, monoclonal gammopathy, benign
51 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Lifestyle makeover may slow early myeloma
Disease control Not yet recruitingThis study tests whether a year-long lifestyle program (diet, exercise, and other healthy habits) can improve key blood markers in people with MGUS or smoldering myeloma—two early, often symptom-free conditions that can lead to multiple myeloma. About 67 adults will participate, …
Phase: NA • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a Korean-Mediterranean diet slow early myeloma?
Disease control Not yet recruitingThis pilot study will test whether a 12-week Korean-style Mediterranean diet, combined with daily step tracking, is feasible for people with MGUS or smoldering myeloma. Twenty adults will receive dietary counseling and a wearable device to monitor activity. Researchers will measu…
Phase: NA • Sponsor: Seoul National University Bundang Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Simple blood test could spot hidden myeloma years early
Diagnosis Not yet recruitingThis study tests a new blood test that looks for DNA fragments in the blood (called cfDNA) to detect multiple myeloma and its early forms (MGUS and smoldering myeloma) in people over 40. The test uses machine learning to tell the difference between healthy individuals and those w…
Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Diagnosis
Last updated Jul 08, 2026 00:00 UTC
-
New scan spots hidden organ damage before symptoms start
Diagnosis Not yet recruitingThis study explores whether a PET/MR scan using a radioactive tracer called 18F-Florbetaben can detect amyloid deposits—abnormal protein clumps that can damage organs—in people with certain blood disorders. Participants receive a single injection of the tracer followed by a whole…
Phase: NA • Sponsor: University of Zurich • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Massive study to uncover hidden link between blood mutations and immune disorders
Knowledge-focused Not yet recruitingThis study will follow 5,000 adults with immune system problems to see if certain blood cell mutations (called clonal hematopoiesis) are linked to their condition. Researchers will track new cases of immune-related diseases over time. No treatments or drugs are tested—this is pur…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC